GLP-1 Drugs Like Ozempic Linked to 62% Drop in Impulsivity-Driven Violence

GLP-1 receptor agonists like Ozempic and Wegovy have already reshaped conversations around obesity, diabetes, and metabolic health. Now, a Rutgers University study published in Criminology suggests these widely used medications may also influence behavior in unexpected ways — specifically by weakening the psychological pathway from impulsive thinking to violent action.

The research analyzed survey data from 7,521 U.S. adults collected in 2025, focusing on 821 individuals with prior or current GLP-1 use. Researchers compared current users to former users and examined how medication status affected the relationship between violent behavior, impulsivity, and alcohol consumption. Violent behavior was measured using a validated self-report tool covering fighting, assault, and robbery.

The headline finding: the link between impulsivity and violent behavior was approximately 62% weaker in current GLP-1 users versus former users. The alcohol-violence connection was about 52% weaker among active users, though this result was less consistent across sensitivity analyses. These are striking reductions in established risk pathways, not just marginal statistical differences.

Researchers offered a compelling mechanistic hypothesis — that GLP-1 drugs may function similarly to cognitive behavioral therapy, dampening the translation of impulse into action rather than removing impulsivity altogether. This aligns with emerging evidence that GLP-1 receptors are expressed in brain regions governing reward, self-control, and emotional regulation, not just appetite centers.

Important caveats apply. This is a cross-sectional, observational study, meaning it captures a snapshot in time and cannot establish cause and effect. Self-reported violent behavior may be underreported. The sample of GLP-1 users, while substantial, was drawn from a single survey. Longitudinal and experimental trials are needed to confirm whether GLP-1 medications genuinely reduce violence risk and to clarify the underlying neurobiological mechanisms. Still, for health-conscious individuals already using or considering GLP-1 therapy, these findings add a compelling new dimension to the drug class's potential benefits.